- ￥291 - 4363
- MedChemExpress(MCE)
- 美国
- HY-10993
- 2025年12月05日
企业认证
相关产品推荐更多 >
Propargyl-PEG3-amine,932741-19-0
￥140
T025,2407433-00-3
￥1800![Methyl 4-hydroxy-2-methyl-2H-thieno[2,3-e][1,2]thiazine-3-carboxylate 1,1-dioxide (Standard)2-甲基-4-羟基-2H-噻吩并[2,3-E]-1,2-噻嗪-3-甲酸甲酯1,1-二氧化物(替诺昔康甲合物) (标准品),59804-25-0](https://img1.dxycdn.com/p/s14/2025/1205/453/4870510878871686991.jpg!wh200)
Methyl 4-hydroxy-2-methyl-2H-thieno[2,3-e][1,2]thiazine-3-carboxylate 1,1-dioxide (Standard)2-甲基-4-羟基-2H-噻吩并[2,3-E]-1,2-噻嗪-3-甲酸甲酯1,1-二氧化物(替诺昔康甲合物) (标准品),59804-25-0
询价
Siponimod辛波莫德,1230487-00-9
￥324
Motesanib (Standard)莫替沙尼 (Standard),453562-69-1
￥1080
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 英文名：
AZD1775; MK-1775
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
955365-80-7
- 规格：
10 mM * 1 mL/1 mg/5 mg/10 mg/25 mg/50 mg/100 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥738.0 |
|---|---|---|---|
| 规格： | 1 mg | 产品价格： | ￥291.0 |
| 规格： | 5 mg | 产品价格： | ￥670.0 |
| 规格： | 10 mg | 产品价格： | ￥1079.0 |
| 规格： | 25 mg | 产品价格： | ￥1975.0 |
| 规格： | 50 mg | 产品价格： | ￥3113.0 |
| 规格： | 100 mg | 产品价格： | ￥4363.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Adavosertib
CAS No. : 955365-80-7
MCE 国际站：Adavosertib
产品活性：Adavosertib (AZD-1775; MK-1775) 是一种有效的 Wee1 抑制剂，IC50 值为 5.2 nM。
研究领域：Cell Cycle/DNA Damage
作用靶点：Wee1
In Vitro: Adavosertib (MK-1775) enhances the cytotoxic effects of 5-FU in p53-deficient human colon cancer cells. Adavosertib (MK-1775) inhibits CDC2 Y15 phosphorylation in cells, abrogates DNA damaged checkpoints induced by 5-FU treatment, and causes premature entry of mitosis determined by induction of Histone H3 phosphorylation.
Adavosertib (MK-1775) abrogates the radiation-induced G2 block in p53-defective cells but not in p53 wild-type lines.
The combination of NSC 613327 with Adavosertib (MK-1775) produces robust anti-tumor activity and remarkably enhances tumor regression response (4.01 fold) compared to NSC 613327 treatment in p53-deficient tumors.
In Vivo: In vivo, Adavosertib (MK-1775) potentiates the anti-tumor efficacy of 5-FU at tolerable doses.
Adavosertib (MK-1775) (60 mg/kg twice daily, p.o.) enhances H1299 xenograft tumor response to fractionated radiotherapy.
Adavosertib (MK-1775) (30 mg/kg. p.o.) regresses tumor growth in PANC198, PANC215 and PANC185 as compared to GEM treated mice.
相关产品：Drug Repurposing Compound Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Cell Cycle/DNA Damage Compound Library | Kinase Inhibitor Library | Anti-Cancer Compound Library | Clinical Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Anti-COVID-19 Compound Library | Chemical Probe Library | Anti-Pancreatic Cancer Compound Library | Targeted Diversity Library | Human Metabolite Library | Anti-Prostate Cancer Compound Library | Heterocyclic Compound Library | Serine/Threonine Kinase Inhibitor Library | RP-6306 | PD0166285 | PD 407824 | WEE1-IN-5 | WEE1-IN-3 | RSS0680 | DB0614 | WEE1-IN-4 | Pomalidomide-C3-adavosertib | Bosutinib isomer | LEB-03-144 | LEB-03-145 | LEB-03-146 | LEB-03-153
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
技术资料暂无技术资料 索取技术资料
